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Abstract
Andes virus (ANDV) is the predominant cause of hantavirus pulmonary syndrome (HPS) in South America and the only
hantavirus known to be transmitted person-to-person. There are no vaccines, prophylactics, or therapeutics to prevent or
treat this highly pathogenic disease (case-fatality 35–40%). Infection of Syrian hamsters with ANDV results in a disease that
closely mimics human HPS in incubation time, symptoms of respiratory distress, and disease pathology. Here, we evaluated
the feasibility of two postexposure prophylaxis strategies in the ANDV/hamster lethal disease model. First, we evaluated a
natural product, human polyclonal antibody, obtained as fresh frozen plasma (FFP) from a HPS survivor. Second, we used
DNA vaccine technology to manufacture a polyclonal immunoglobulin-based product that could be purified from the eggs
of vaccinated ducks (Anas platyrhynchos). The natural ‘‘despeciation’’ of the duck IgY (i.e., Fc removed) results in an
immunoglobulin predicted to be minimally reactogenic in humans. Administration of $5,000 neutralizing antibody units
(NAU)/kg of FFP-protected hamsters from lethal disease when given up to 8 days after intranasal ANDV challenge. IgY/
IgYDFc antibodies purified from the eggs of DNA-vaccinated ducks effectively neutralized ANDV in vitro as measured by
plaque reduction neutralization tests (PRNT). Administration of 12,000 NAU/kg of duck egg-derived IgY/IgYDFc protected
hamsters when administered up to 8 days after intranasal challenge and 5 days after intramuscular challenge. These
experiments demonstrate that convalescent FFP shows promise as a postexposure HPS prophylactic. Moreover, these data
demonstrate the feasibility of using DNA vaccine technology coupled with the duck/egg system to manufacture a product
that could supplement or replace FFP. The DNA vaccine-duck/egg system can be scaled as needed and obviates the
necessity of using limited blood products obtained from a small number of HPS survivors. This is the first report
demonstrating the in vivo efficacy of any antiviral product produced using DNA vaccine-duck/egg system.
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Introduction
Andes virus (ANDV) is responsible for the majority of
hantavirus pulmonary syndrome (HPS) cases in the South
American countries of Argentina, Brazil, Chile, and Uruguay
[1]. Between 1995–2008, over 700 reported cases of HPS in
Argentina alone [2], 680 in Chile (1995–2010) [3], and 884 in
Brazil (1993–2007) [4] with more cases throughout South,
Central, and North America. Infection is thought to occur
primarily through inhalation or ingestion of rodent excreta, or
by rodent bites. However, there is convincing evidence that
ANDV can be transmitted from person-to-person, resulting in
clusters of cases [5,6]. The case-fatality-rate for HPS is
approximately 40% and there are currently no licensed vaccines,
therapeutics, or postexposure prophylactics for this disease [7].
Efforts to develop medical countermeasures to prevent and treat
HPS have been bolstered by the use of the ANDV/Syrian hamster
model of lethal HPS. This model accurately mimics human HPS
disease in incubation time, tropism to endothelial cells, thrombo-
cytopenia, neutrophilia, lung pathology including pulmonary
edema and pleural effusion, and shock [8,9,10,11,12,13]. The
ANDV/Syrian hamster model has been used to evaluate proof-of-
concept vaccines [14,15] and postexposure prophylactics [14,16].
Historically, one of the most effective approaches to prevent and
treat persons exposed to pathogenic viruses has been the use of
antiserum. For example, persons potentially exposed to rabies
virus are administered rabies antiserum, and are then vaccinated.
Similarly, antiserum has been used to successfully treat Argenti-
nean hemorrhagic fever [17,18]. Passive vaccination to prevent
hantavirus disease was previously investigated in our laboratory.
We demonstrated that plasma from a HPS survivor was sufficient
to protect in the ANDV/hamster model [14]. We also found that
serum containing neutralizing antibodies collected from rhesus
macaques or rabbits vaccinated with a DNA vaccine containing
the M segment of ANDV (pWRG/AND-M) protected hamsters
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to 5 days postchallenge [16]. These studies clearly demonstrated
that passive protection using nonpurified polyclonal antibodies
collected from survivors, or produced using DNA vaccine
technology, can be an effective approach to preventing hantavirus
disease even when administered days after exposure.
Despite the promising role of antibodies as ANDV immu-
notherapeutics, there are no neutralizing monoclonal antibodies
and human convalescent sera are very rare. While our previous
work using sera from nonhuman primates and rabbits suggests
using antibodies from these animals may be a viable option, the
risks of reactogenicity, including serum sickness, are high [19]. A
possible solution is the use of duck-generated antibodies. Ducks
produce three immunoglobulin isotypes, IgM, IgA, and IgY.
Expression of the IgY isotype can be alternatively spliced creating
an IgY lacking the Fc region (IgYDFc) in hypervaccinated ducks
[20,21]. Because the Fc region is predominantly responsible for
reactogenicity [22], a truncated isoform is an attractive option
when neutralization is the primary goal. Ducks have been
vaccinated with purified detoxified venom antigens from various
snakes, and the IgYDFc purified from egg yolks and tested in the
development of antitoxins [23]. This strategy has been evaluated
in a hepadnavirus infection model. In that study, ducks were
vaccinated with a DNA vaccine encoding hepadnavirus envelope
proteins. The eggs from the ducks contained IgYDFc and
ducklings produced by the vaccinated ducks were protected
against hepadnavirus challenge [24,25]. This approach has also
been evaluated in a mouse influenza model where IgY from
vaccinated laying chickens protects mice from lethal highly
pathogenic avian influenza [26].
Here, we used human polyclonal antibodies (i.e., fresh frozen
plasma from an HPS survivor) to define the dose in neutralizing
units required to protect, and the pre-disease onset timeframe
required for effective treatment. In addition, we explored the
concept of manufacturing antiviral neutralizing polyclonal anti-
bodies in ducks using DNA vaccine technology, purifying the
candidate product from duck egg yolks, and testing the material in
an animal model of lethal HPS. We demonstrate, for the first time,
that it is possible to manufacture a polyclonal postexposure
prophylactic product that targets a lethal viral disease using a
combination of DNA vaccine and duck egg technology.
Materials and Methods
Ethics statement
Research was conducted in compliance with the Animal
Welfare Act and other federal statutes and regulations relating
to animals and experiments involving animals and adheres to
principles stated in the Guide for the Care and Use of Laboratory
Animals, National Research Council, 1996. The facilities where
this research was conducted are fully accredited by the Association
for Assessment and Accreditation of Laboratory Animal Care
International. All animal experiments were approved by USAM-
RIID’s Institutional Animal Care and Use Committee (approval
ID AP-08-008). Human plasma was collected with written
informed consent in accordance with an NIH sponsored clinical
protocol approved by the Comite ´ de Etica de la Investigacio ´n,
Centro De Bioe ´tica Facultad de Medicina , Clı ´nica Alemana,
Universidad del Desarrollo (funded by NIH U01AI045452).
Animal work involving passive transfer of human plasma was
approved by the USAMRIID Human Use Committee, under
Exemption Certificate FY07-20, HP-07-20.
Virus and cells
A twice plaque-purified ANDV strain Chile-9717869 passaged
two times in Vero E6 cells (Vero C1008 ATCC CRL 1586,
Manassas, VA) was described previously [27]. Cells were
maintained in Eagle’s minimal essential medium with Earle’s salts
(EMEM) supplemented with 10% fetal bovine serum (FBS),
10 nM HEPES (pH 7.4), 200 U/ml penicillin, 200 mg/ml strep-
tomycin, 16 nonessential amino acids (NEAA), 1.5 mg/ml
amphotericin B, and 50 mg/ml gentamicin sulfate (cEMEM) at
37uC in a 5% CO2 incubator.
Anti-ANDV FFP
Fresh frozen plasma (FFP) was obtained, with informed consent,
from a convalescent HPS patient infected with ANDV. Typically,
FFP is frozen within 8 h of collection at a temperature of at least
220uC. Before use in passive transfer experiments, a-ANDV FFP
and normal FFP were thawed on wet ice, heat inactivated (56uC,
30 min) and aliquoted.
PRNT
Plaque reduction neutralization tests (PRNT) were performed as
previously described [11]. Briefly, heat-inactivated serum samples
(56uC for 30 min) were diluted in cEMEM. Samples containing
purified IgY/IgYDFc were not heat-inactivated. These dilutions
were mixed with an equal volume of approximately 75 PFU of
ANDV with or without guinea pig or human complement at a
final concentration of 5% (Accurate Chemical and Scientific
Corp., Westbury, NY). This mixture was incubated overnight at
4uC and then a plaque assay was performed as described by using
7-day old Vero E6 monolayers in 6-well plates. After 7 days,
monolayers were stained with neutral red (Invitrogen, Carlsbad,
CA) and plaques were counted 2 days (37uC) after staining.
Complement has been reported to enhance hantavirus neutraliz-
ing antibody titers for certain samples, and consequently our
standard PRNT includes complement [11,16,27]. PRNT titers
represent the highest serum dilution which neutralizes 80% of the
plaques in control (no serum) wells. Neutralizing antibody units
(NAU) are the PRNT80 value per ml. For example, a sample with
a PRNT80 value of 2560 would have 2560 NAU/ml.
Intranasal and intramuscular injection of hamsters with
virus
Female Syrian hamsters (Mesocricetus auratus) weighing 150 to
200 g (Harlan, Indianapolis, IN) were anesthetized by an
intramuscular (i.m.) injection with approximately 0.1 ml/100 g
of body weight of ketamine-acepromazine-zylazine mixture. For
intranasal (i.n.) injections, anesthetized hamsters were adminis-
tered 50 ml delivered as 25 ml per nare with a plastic pipette tip
(4,000 PFU ANDV total, 42 LD50). Intramuscular (i.m.) injections
in the caudal thigh consisted of 2,000 PFU (250 LD50) or 200 (25
LD50) of ANDV diluted in PBS to a volume of 0.2 ml. After viral
challenge, hamsters were placed in isolator units (one to four
hamsters per cage). Groups of 8 hamsters were typically used for
experimental treatments, unless otherwise stated. All work
involving hamsters was performed in an animal biosafety level 4
(ABSL-4) laboratory. Hamsters were observed two to three times
daily. Subcutaneous [17] injections of test article were conducted
in the scruff of the neck with 0.5–1 ml volume.
Vaccination of ducks
Khaki Campbell ducks (Anas platyrhynchos) were received as
hatchlings and raised in a facility isolated from all other species.
Ducks were vaccinated at approximately 7 months of age (average
Duck Antibody-Based Immunoprophylactic for HPS
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electroporation event. Ducks were initially vaccinated with a
priming dose of 320 mg pWRG/AND-M delivered over two sites
in the breast muscle with a twin injection device (Inovio, Blue Bell,
PA). Thereafter, 160 mg of the plasmid was delivered bilaterally on
days 14, 28, 56, 70, 84, and 252. Nonresponsive ducks, as
measured by PRNT, were removed from the study while
remaining ducks were vaccinated with 1 mg total dose adminis-
tered bi-laterally with the TriGrid device (Ichor Medical Systems,
San Diego, CA) on days 483, 504, 525, 553, and 588. Duck eggs
were collected and cracked and the contents gently transferred to a
yolk separator to allow a majority of the egg white to separate by
gravity from the yolk. A razor blade was used to cut the egg white
on the outside of the yolk separator taking care not to damage the
yolk sac. The yolk sac was then transferred to a paper towel and
gently rolled to allow any remaining egg white to adhere. The yolk
sac, typically 20 cc per egg, was transferred to a 2 L bottle. This
procedure was repeated until the desired number of duck eggs had
been pooled.
Duck IgY/IgYDFc purification from eggs
The egg yolks were diluted 10-fold in water and the pH of the
mixture was adjusted to 5.0 with HCl. The diluted yolk suspension
was agitated gently for 4 h at 4uC then centrifuged at 10,0006g
for 30 min at 4uC. The semi-clarified supernatant was mixed with
CelpureH P300 (Advanced Minerals Corporation, Goleta, CA) to a
final concentration of 10% w/v by rolling the bottles and was then
filtered through pre-caked GF/A filters (Whatman, Piscataway,
NJ). The resulting filtrate then undertook 10 diavolumes of
exchange into 10 mM Tris, pH 7.0 on a Pellicon II PES 100 kD
MWCO (Millipore, Billerica, MA) tangential flow filter. Solid PEG
6000 (Fluka, Fuchs, Switzerland) was added to the solution to a
final concentration of 20% w/v and was allowed to dissolve by
mixing at room temperature for 30 min. The solution was then
centrifuged at 10,0006g for 30 min at 4uC. After centrifugation
the supernatant solution was discarded and the resulting pellet was
dissolved in 50 mM Tris-HCl, pH 9.0 (Sigma-Aldrich, St. Louis,
MO). A Fractogel TMAE (trimethylaminoethyl) (EMD Chemicals,
Gibbstown, NJ) column was equilibrated with five bed volumes of
50 mM Tris-HCl, pH 9.0. The dissolved PEG fractionation pellet
was then loaded onto the column and the load flow through was
discarded. The column was washed with twenty bed volumes of
50 mM Tris-HCl to remove residual PEG 6000. The IgY was
eluted from the column with four bed volumes of 50 mM Tris-
HCl, pH 9.0 containing 500 mM NaCl. The IgY rich fraction was
then exchanged with 12 diavolumes of phosphate buffered saline
(pH 7.4). The concentration of the purified IgY/IgYDFc was
determined with a BSA standard based assay (Bio-Rad, Hercules,
CA) and 280 nm absorbance relative to known IgY standards
(Gallus).
Western Blot Analysisz
IgY/IgYDFc samples were separated in a 4–12% SDS-PAGE
run under nonreducing conditions and blotted onto a PVDF
membrane (Invitrogen, Carlsbad, CA). IgY, IgYDFc, and antibody
components were detected with a mouse monoclonal antibody to
duck IgY, clone 16C7 (Thermo Fisher Scientific, Waltham, MA).
Signals were visualized using chemiluminescence SuperSignal
West Femto Substrate kit according to the manufacturer’s
instructions (Thermo Fisher Scientific, Waltham, MA). Signals
were captured using GeneSnap software and a G:Box Imaging
system (Syngene, Frederick, MD). Signal intensities were analyzed
using GeneTools (Syngene, Frederick, MD).
ELISA
Antibodies to the ANDV nucleocapsid (N) protein cross-react
with purified Puumala virus N in an established ELISA [13,28].
This Puumala N-based ELISA was used to detect evidence of
ANDV infection in hamsters exposed to ANDV as described
previously. All hamster serum samples were gamma-irradiated (on
dry ice) with 3610
6 rads from a
60Cobalt source and then heat-
inactivated (56uC, 30 minutes) before being serial-diluted (10-fold
dilutions starting at 1:100) and evaluated in the ELISA. Specific
O.D. values are obtained by subtracting values from the sera
sample using a negative control his-tagged protein as the solid
phase antigen. Endpoint titers are defined as the highest dilution
that produces a specific O.D. value.than mean of three negative
control sera plus three standard deviations.
Statistical Analysis
Half-life was calculated by nonlinear regression analysis using a
sigmoidal dose response with variable slope. Survival data ere
analyzed using Fisher’s exact test (two-tailed). Mean day-to-death
was analyzed using Mann-Whitney U test (two-tailed). Differences
between antibody titers were analyzed using the student’s t-test
(two-tailed). P values of less than 0.05 were considered significant.
All statistical analyses were performed using GraphPad Prism (La
Jolla, CA) version 4.
Results
Neutralizing activity and bioavailability of anti-ANDV FFP
used in hamster passive transfer experiments
FFP from a Chilean HPS survivor and normal human FFP were
tested for a capacity to neutralize ANDV by PRNT. Four
independent PRNT80 were performed. The geometric mean titer
(GMT) for the a-ANDV FFP was calculated to be 10,240 (Fig. 1A,
Table 1). Neutralizing antibodies were not detected in normal
human FFP.
Before performing passive transfer protection experiments, we
measured the bioavailability of human neutralizing antibodies in
hamsters injected with a-ANDV FFP. Groups of three animals
were injected with either a high dose (64,000 NAU/kg) of a-
ANDV FFP by either s.c. or i.m. routes or a lower dose (12,000
NAU/kg) of a-ANDV FFP by the s.c. route. Serum samples were
obtained on days 1, 2, 3, 4, 10, 15, and 21, and neutralizing
antibody titers were determined by PRNT (Fig. 1B). There was
no statistical difference in the levels of neutralizing antibodies
detected in hamster sera when a-ANDV FFP was administered at
64,000 NAU/kg by either s.c. or i.m. routes. Half-lives in hamster
sera were calculated to be 7.7 days and 6.8 days when a-ANDV
FFP was administered s.c. or i.m., respectively. Neutralizing
antibodies were still detected on the last time-point tested (day 21).
a-ANDV FFP administered at 12,000 NAU/kg s.c. was detectable
for 3 days, then dropped below level of detection for a PRNT80.
Plotting PRNT50 titers shows a-ANDV FFP is detectable out to 9
days. The half-lives of a-ANDV FFP administered at 12,000
NAU/kg are 4.2 days according to PRNT80 titers and 4.7 days
according to PRNT50 titers. All of the protection experiments
described below involved s.c. passive transfer.
a-ANDV FFP effectively protects hamsters from lethal
ANDV challenge
We next determined the protective efficacy of a-ANDV FFP
when administered at time-points post-ANDV challenge. Ham-
sters were challenged with 4,000 PFU of ANDV i.n. on day 0 and
then received a single injection of 30,720 NAU/kg of a-ANDV, or
Duck Antibody-Based Immunoprophylactic for HPS
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a-ANDV FFP administered on day 5 or 8 postchallenge was 100%
effective at preventing lethal HPS disease in hamsters as
determined by survival analysis. a-ANDV FFP administered on
day 12 was 63% efficacious; however, this protection was not
statistically significant in comparison to normal FFP (P=0.0769)
(Fig 2A).
To determine if surviving hamsters had been productively
infected, sera from Figure 2 were subjected to a hantavirus
nucleocapsid ELISA. Unexpectedly, hamsters receiving a-ANDV
FFP on days 5 or 8 postchallenge had undetectable levels of a-
nucleocapsid antibodies (Fig. 2B). These levels increased in
surviving hamsters receiving a-ANDV FFP on days 12 and 15. By
comparison, hamsters that received positive control a-ANDV
rabbit sera (1,920 NAU/kg) on day 5 postchallenge had similar
levels of antibodies compared to surviving hamsters that had
received normal FFP or no antibody treatment. These data
indicate that passive transfer of high levels of neutralizing
antibodies can not only protect against lethal disease, but also
can contain the infection in a manner that actually limits or, in
some cases, prevents seroconversion (P=0.0004 on a-ANDV FFP
day 5 and P=0.0005 on a-ANDV FFP day 8). Furthermore, these
data demonstrate that even very high levels of neutralizing
antibodies cannot protect against an i.n. challenge when
administered on or after day 12, 5 days before the mean-day-
death (day 17).
Titration of anti-ANDV FFP protective dose in hamsters
Based on the results from the previous experiment showing
undiluted a-ANDV FFP protected hamsters from lethal HPS, we
next titrated the minimal dose of a-ANDV FFP required to elicit
protection when administered post-ANDV challenge (4,000 PFU
i.n.). Undiluted a-ANDV FFP (30,720 NAU/kg) along with 1:6
and 1:12 dilutions of a-ANDV FFP (corresponding to 5,120 and
2,560 NAU/kg) were passively transferred to ANDV-infected
hamsters on day 8 postchallenge. Day 8 was selected based on the
results in Figure 2 demonstrating that day 8 was the latest time-
point that resulted in significant protection when a high dose of a-
Figure 1. a-ANDV FFP effectively neutralizes ANDV in vitro and is detectable in hamsters after passive transfer. A) Neutralizing
antibody titers were determined by ANDV PRNT80 performed on a-ANDV FFP and normal human serum. * indicates results are statistically significant.
B) Neutralizing antibody bioavailability was determined by ANDV PRNT80 performed on hamster serum samples collected after passive transfer of a-
ANDV FFP (64,000 NAU/kg) by either s.c. or i.m. route (3 hamsters per group) on day 0, through 21 days. PRNT80 titers represent the lowest serum
dilution neutralizing 80% of the plaques relative to the control (no serum). PRNT50 values of a single group are denoted by a dashed line.
doi:10.1371/journal.pone.0035996.g001
Table 1. a-ANDV FFP and a-ANDV duck IgY/IgYDFc stocks used per experiment.
Figure a-ANDV Stock
a
Concentration
(mg/ml)
Dosage (mg/
100 g hamster) PRNT80
Neutralizing antibody
dosage (NAU/kg)
Neutralizing antibody
units (NAU/ml)
1 FFP N/A N/A 10240 64000 10240
2 FFP N/A N/A 10240 30720 10240
3 FFP N/A N/A 10240 30720, 5120,2560 10240
5,6 FFP N/A N/A 10240 12000 10240
4D IgY/IgYDFc Lot #1 11.4 4.56 1280 5000 1280
4B,5 IgY/IgYDFc Lot #2 11.1 1.30 10240 12000 10240
6 IgY/IgYDFc Lot #3 15.5 7.25 2560 12000 2560
4A, 4C IgY/IgYDFc Lot #4 12.8 6.00 2560 12000 2560
2 Rabbit Sera N/A N/A 640 1920 640
aFFP, fresh frozen plasma or duck IgYDFc purified from vaccinated duck eggs.
doi:10.1371/journal.pone.0035996.t001
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dilutions of a-ANDV FFP uniformly protected hamsters from
ANDV-induced lethal HPS disease (Fig. 3A). Hamsters receiving
the 1:12 dilution of a-ANDV FFP had 63% survival, which was
not statistically significant (P=0.0707).
To determine if survivors had been productively infected, sera
from surviving hamsters were subjected to nucleocapsid ELISA.
Similar to the ELISA results in Figure 2B, hamsters receiving high
dosages of a-ANDV FFP had low levels of a-ANDV antibodies
(Fig. 3B). Of the hamsters receiving undiluted a-ANDV FFP, 5 of
the 8 failed to develop a detectable immune response titers $2 (log
10). Of the hamsters receiving the 1:6 or 1:12 dilution, 75–80%,
respectively, generated detectable humoral immune responses
(P=0.0005 for undiluted, P=0.0005 for 1:6, and P=0.0023 for
1:12, when compared to rabbit sera positive controls). Together,
these data indicate that a single dose of a-ANDV FFP at $5,000
NAU/kg 8 days after exposure (9 days before mean day-to-death,
8 days prior to symptom onset) was sufficient to confer significant
protection against lethal HPS. Moreover, higher doses of
neutralizing antibodies not only protected against lethal disease,
but also protected against productive infection as measured by
seroconversion.
A 12,000 NAU/kg dose of a-ANDV duck IgY/IgYDFc is
sufficient to protect hamsters from lethal ANDV i.n.
challenge
Work with the human a-ANDV FFP demonstrated that it was
feasible to use polyclonal a-ANDV antibodies at doses as low as
5,000 NAU/kg to protect against lethal disease, and higher doses
could be used to confer protection at later timepoints postexpo-
sure. If a polyclonal a-ANDV product could be manufactured,
rather than obtained from consenting survivors, then this could
provide a more consistent and unlimited source of postexposure
prophylactic product to treat persons potentially exposed to
ANDV. Towards this goal, we examined a novel approach to
producing a candidate postexposure prophylactic to protect
against HPS. This approach involved the production of polyclonal
antibodies in the eggs of vaccinated ducks, and the purification of
IgY and the truncated form of the antibody, IgYDFc, from egg
yolks. Ducks were vaccinated with the ANDV DNA vaccine,
pWRG/AND-M, as described in the Methods section. Sera were
screened for ANDV neutralizing antibodies by PRNT (data not
shown). Eggs from ducks with high serum neutralizing antibody
levels were collected. Ig was purified from egg yolks and samples
were visualized by Western blot. Under nonreducing conditions
using an a-duck IgY antibody, it is possible to visualize the IgY
band, in addition to the truncated form IgYDFc and heavy chain
(HC) (Fig. 4A). Using signal intensity software, it was determined
that the IgYDFc and HC bands composed approximately 75% of
the protein visualized by Western blot. Subsequently, the ability of
purified a-ANDV duck IgY/IgYDFc to neutralize ANDV was
evaluated in vitro using the PRNT assay. The a-ANDV duck IgY/
IgYDFc had potent neutralizing activity, with PRNT80 titers of
10240, which was the same a -ANDV PRNT80 titer in human
convalescent FFP (Fig. 4B).
As with a-ANDV FFP, the bioavailability of duck a-ANDV
IgY/IgYDFc was assessed in the hamster. Three hamsters each
were injected with 12,000 NAU/kg or 64,000 NAU/kg of a-
ANDV duck IgY/IgYDFc by the s.c. route. Serum samples were
collected on days 1, 3, 10, 15, and 21, and PRNT80 titers were
determined. PRNT80 titers from hamsters administered 64,000
NAU/kg had similar levels to a-ANDV FFP on day 1; however,
Figure 2. a-ANDV FFP passively transferred on days 5 and 8 protects hamsters from lethal disease and infection. A) Survival curve of
hamsters challenged with 4,000 PFU i.n. of ANDV on day 0, then passively transferred with a-ANDV FFP (30,720 NAU/kg) on days 5, 8, 12 or 15
postinfection. Rabbit sera (administered at 1,920 NAU/kg) were collected 102 days post DNA vaccination [16]. P-values were determined based on
comparison to normal serum on matching day. B) a-N ELISA endpoint titers (log10) were conducted with sera from surviving hamsters challenged
with ANDV in A). GMT for each group are shown. * indicates results are statistically significant when compared to rabbit sera positive control.
doi:10.1371/journal.pone.0035996.g002
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Plotting PRNT50 titers shows detectable titers to 6 days, with half-
lives calculated to be 2.9 days for PRNT80 titers and 2.3 days for
PRNT50 titers. Low neutralization titers were found after
administration of 12,000 NAU/kg duck a-ANDV IgY/IgYDFc
on days 1 and 3, which then dropped below the level of detection
of the assay on subsequent days (Fig. 4C). Half-lives were 3.0 days
based on PRNT80 titers and 2.9 days based on PRNT50 titers.
Because 5,120 NAU/kg of a-ANDV FFP protected 100% of
hamsters from lethal ANDV challenge, approximately the same
concentration of purified a-ANDV duck IgY/IgYDFc was tested
for a capacity to protect in the HPS model. Hamsters were
challenged with 4,000 PFU of ANDV i.n. on day 0 and then
administered 5,000 NAU/kg of duck a-ANDV IgY/IgYDFc (Lot
#1) on day 8 postchallenge (Table 1). Unexpectedly, this
concentration did not have a significant effect on the outcome of
ANDV challenge (Fig. 4D). This indicated that either purified
duck a-ANDV IgY/IgYDFc was not capable of neutralizing
ANDV in vivo, or the dosage of purified a-ANDV duck IgY/
IgYDFc required for protection was higher than 5,000 NAU/kg.
To test the possibility that a higher dose of a-ANDV IgY/
IgYDFc might confer protection, groups of 8 hamsters were
challenged with 4,000 PFU i.n. of ANDV on day 0, and were then
administered duck a-ANDV IgY/IgYDFc (Lot #2) at two
concentrations, 12,000 and 20,480 NAU/kg, on either day 5 or
8 post-challenge (Table 1). a-ANDV FFP at 12,000 NAU/kg was
included as a positive control. Purified normal duck IgY and
untreated hamsters were included as negative controls. As
expected, a-ANDV FFP administered on day 5 elicited complete
protection. Hamsters receiving 12,000 NAU/kg of a-ANDV duck
IgY/IgYDFc on day 5 were also significantly protected (88%
survival, P=0.0073). Hamsters receiving 20,480 NAU/kg of a-
ANDV duck IgY/IgYDFc had decreased survival (63% survival,
P=0.0977); which is not statistically significant when compared to
normal duck IgY. (Fig. 5A). When 12,000 NAU/kg of either a-
ANDV FFP or duck a-ANDV IgY/IgYDFc (Lot #2) were
administered 8 days post-ANDV challenge, a-ANDV FFP
completely protected hamsters (100% survival, P=0.0009);
whereas duck a-ANDV IgY/IgYDFc exhibited incomplete
protection (63% survival, P=0.0977) (Fig. 5B) that was not
statistically significant compared to negative controls.
To determine if hamsters had been productively infected, sera
from surviving hamsters were subjected to a nucleocapsid ELISA.
Hamsters receiving a-ANDV FFP on days 5 or 8 had lower levels
of a-nucleocapsid antibodies when compared to hamsters
receiving the same 12,000 NAU/kg dose of duck a-ANDV IgY/
IgYDFc (Fig. 5C) suggesting that human FFP was more effective
at limiting infection than the duck IgY/IgYDFc having the same in
vitro neutralizing activity. When compared to no antibody
controls, the reduction of the FFP ELISA titer was statistically
significant (P=0.0148 on day 5 and P=0.0097 on day 8) while the
duck IgY/IgYDFc was also statistically significant (P=0.0043 on
Figure 3. 5,000 NAU/kg of a-ANDV FFP is sufficient to protect hamsters from lethal HPS disease. A) Survival curve of hamsters
challenged with 4,000 PFU of ANDV i.n. on day 0 and passively transferred with dilutions of a-ANDV FFP on day 8. P-values were determined by
comparing FFP dilution to no antibody control. B) a-N ELISA endpoint titers (log10) were conducted with sera from surviving hamsters challenged
with ANDV in A). GMT for each group are shown.
doi:10.1371/journal.pone.0035996.g003
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of duck a-ANDV IgY/IgYDFc administered 5 or 8 days after .i.n.
exposure limited infection but only the treatment on day 5 was
effective at conferring a significant level of protection against lethal
disease.
Direct comparison of a-ANDV FFP and duck a-ANDV IgY/
IgYDFc for a capacity to protect hamsters from lethal
ANDV i.m. challenge
Having found that the manufactured a-ANDV IgY/IgYDFc
was capable of conferring protection in the i.n. model, we were
interested in testing whether this material could protect in a more
aggressive i.m. challenge model. When Syrian hamsters were
challenged i.m. with 200 PFU of ANDV the mean day-to-death
was 11, which was 7 days earlier than the mean day-to-death in
the i.n. model [16]. Groups of 8 to 16 hamsters were challenged
with 200 pfu of ANDV by the i.m. route and then, 5 days after
exposure, the hamsters were treated with 12,000 NAU/kg of
either a-ANDV FFP or a-ANDV IgY/IgYDFc. Both a-ANDV
FFP and a-ANDV duck IgY/IgYDFc conferred protection to 75%
of the hamsters in each group (FFP n=8, duck IgYDFc n=16)
(Fig. 6A). Protection was statistically significant when compared to
hamsters receiving nonspecific duck IgY with P values of 0.0118
and 0.0003, respectively.
To determine if surviving hamsters had been productively
infected, sera from surviving hamsters were subjected to
nucleocapsid ELISA. All surviving hamsters receiving either a-
ANDV FFP or a-ANDV duck IgY/IgYDFc mounted an immune
response to ANDV indicating all animals were productively
infected, but nevertheless protected from lethal disease (Fig. 6B).
These results demonstrate a-ANDV FFP and a-ANDV duck IgY/
IgYDFc are capable of protecting from lethal ANDV infection by
both the respiratory and intramuscular challenge routes when
administered 5 days postinfection.
Discussion
Previous passive transfer studies using the ANDV/hamster
model revealed that it was possible to use a postexposure
prophylactic to protect against HPS [14,16]. This experimental
work, coupled with epidemiologic studies demonstrating that
ANDV was associated with person-to-person transmission [5],
indicated that it should be possible to use a-ANDV neutralizing
antibodies to treat and/or prevent disease among close contacts of
Figure 4. Neutralizing activity of a-ANDV duck IgY/IgYDFc in vitro and in vivo. A) Western blot analysis of IgY components recognized by a-
duck IgY antibodies. A) represents IgY/IgYDFc by Western blot with SDS-PAGE run under non-reducing conditions and probed with an a-duck IgY
antibody recognizing the heavy chain of both IgY and IgYDFc. HC is the heavy chain of IgY. B) Percent neutralization of a-ANDV FFP and a-ANDV
duck IgYDFc measured by ANDV PRNT. Dotted line represents 80% neutralization (PRNT). C) Neutralizing antibody bioavailability was determined by
ANDV PRNT performed on hamster serum samples collected after passive transfer of a-ANDV duck IgYDFc (12,000 NAU/kg and 64,000 NAU/kg) by
the s.c. route on day 0, through 21 days. PRNT80 titers (solid lines) and PRNT50 titers (dashed lines) are plotted. D) Survival curve of hamsters
challenged with 4,000 PFU of ANDV i.n. on day 0 and passively transferred with 5,000 NAU/kg of a-ANDV duck IgYDFc on day 8 postinfection.
doi:10.1371/journal.pone.0035996.g004
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neutralizing antibodies before contacts of HPS cases show any
signs of disease. A clinical trial addressing this possibility using a-
ANDV FFP is ongoing in Chile (unpublished data). If a-ANDV
FFP shows promise in the clinical trials, the issue of how to obtain
sufficient quantities of immune plasma for clinical use remains a
challenge. The necessity of using blood group-typed immune
plasma for patients increases the complexity of using a-ANDV
FFP. Like many zoonotics, HPS can be unpredictable in a natural
setting and therefore, estimating the location, timing, and
magnitude of outbreaks is difficult. Moreover, ANDV is a category
A agent on the NIAID list of potential biological threat agents. In
the event of a large-scale outbreak, the emergency use of FFP
collected from consenting HPS survivors would likely be
inadequate as a response or deterrent. Other approaches that
have been used to produce immunotherapeutics to viral diseases
include collecting sera from persons vaccinated with a licensed
vaccine (examples include hepatitis B virus, cytomegalovirus,
vaccinia virus, and rabies virus [29]) or developing protective
monoclonal antibodies (e.g., Synagis for treatment of respiratory
Figure 5. 12,000 NAU/kg of a-ANDV FFP and a-ANDV duck IgY/IgYDFc protects hamsters from lethal HPS disease. A) and B) Survival
curve of hamsters that were challenged with 4,000 PFU i.n. of ANDV on day 0 and passively transferred with a-ANDV FFP or a-ANDV duck IgY/IgYDFc
on day 5 postinfection (A) or day 8 postinfection (B). * indicates statistical significance when compared to normal IgY/IgYDFc treatment. C) a-N ELISA
endpoint titers (log10) were conducted with sera from surviving hamsters challenged with ANDV in A) and B). GMT for each group are shown.
* indicates results are statistically significant when compared to no antibody controls.
doi:10.1371/journal.pone.0035996.g005
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advanced development, and there are no ANDV neutralizing/
protective monoclonal antibodies identified. An alternative
approach to develop an a-ANDV immunotherapeutic is to
produce polyclonal antibodies in animals using processes used
routinely to produce a-venoms and a-toxins.
There are several FDA-approved animal-derived polyclonal
immunoglobulin products. Most of these are a-venoms or a-toxins
made in horses or sheep vaccinated with purified detoxified
venoms or toxins obtained from their natural source. For most of
the modern products, enzymatic treatment of the equine or ovine
antibody is performed to ‘‘despeciate’’ the antibody by removing
the heterologous Fc fragment. For example, the FDA recently
approved Anascorp, a papain-treated polyclonal antibody F(ab9)2
against scorpion toxin produced in horses [14,16]. Papain is a
known human allergen, sharing similar antigenic structures with
some dust mite and latex allergens, further limiting its usage for
patients with those known allergies [30,31]. This despeciation
process, enzymatically separating the Fab9 fragments from the Fc,
reduces the possibility of a hypersensitivity reaction to the Fc
fragment, but may retain risk associated with enzyme hypersen-
sitivity. Several years ago, this polyclonal antibody approach was
proposed as a means to defend against viruses and other agents
used as biological weapons [32]. However, it is notable that there
are no licensed animal-derived polyclonal immunoglobulin
products against any viral disease.
Proof-of-concept studies where chickens or, more recently,
ducks were vaccinated with various venoms, toxins, or infectious
agents to produce antibody that could be purified from egg yolks
have been reported [33,34,35]. In most cases, the vaccine antigens
were purified proteins; however, there were reports of the use of
DNA vaccines to produce the IgYDFc in ducks [24,25,36]. Ours is
the first report describing the use of DNA vaccine technology to
produce antiviral polyclonal antibody in duck eggs that were then
tested in vitro and then in vivo as a postexposure prophylactic. This
same DNA vaccine technology could be used to vaccinate equine
or ovine species to develop a-ANDV polyclonal antibodies.
Reconstituted lyophilized plasma from HPS survivors had
previously been shown to protect in the ANDV/hamster lethal
HPS model [14]. In that study, a dose of approximately 50,000
NAU/kg injected i.p. protected 50% of the hamsters challenged
i.m. with 250 LD50 of ANDV. Here, hamsters given at least 5,000
NAU/kg of a-ANDV FFP s.c. as late as 8 days post-ANDV i.n.
challenge were uniformly protected against lethal HPS disease.
Doses of FFP below 5,000 NAU/kg did not confer protection.
Similarly, treatment after day 8 did not confer significant
protection against an i.n. challenge (Fig. 2 and Fig. 3). These
data confirmed that it is possible to use human convalescent
plasma to protect against HPS and continued to refine the
protective dose and treatment window. In general, the data
indicate that a higher dosage of FFP is required to confer
protection as more time elapses after exposure, and that the
treatment window appears to close between 5–9 days before the
mean day-to-death for an i.n. challenge (i.e., day 17). Note that all
of the passive transfer experiments described in this report involve
a single injection of antibody. An actual treatment regime in the
clinic would likely involve multiple dosing to achieve and maintain
a high level of neutralizing activity over time. This would become
of greater importance since the half-life of a-ANDV IgY/IgYDFc
is approximately half of a-ANDV FFP. Such a continuous
treatment regimen also highlights the importance of having
limited reactogenic material, which duck antibodies lacking the
Fc regions is expected to possess.
A notable finding in this study was that a manufactured
product, a-ANDV IgY/IgYDFc, could protect against lethal HPS
to levels similar to human FFP. A dose of 12,000 NAU/kg IgY/
IgYDFc delivered five days postexposure conferred significant
protection in both the i.n. and i.m. challenge models (Fig. 5A and
6A). To our knowledge, this is the first time an antiviral biologic
produced in duck eggs has been used as a postexposure
prophylactic to protect against a lethal viral disease. The
protection was dependent on the day of delivery because 12,000
NAU/kg of IgY/IgYDFc delivered on day 8 was not protective
(Fig. 4D and 5B). This finding indicated that the FFP was more
effective at conferring in vivo protection than IgY/IgYDFc because
a lower dose of 5,000 of FFP was capable of protecting when
delivered on day 8 (Fig. 3). FFP consists primarily of a-ANDV
immunoglobulin with the Fc portion of the antibody intact. This
Fc could be involved in mechanisms of complement dependent
and independent protection not measured in the PRNT including
downstream signaling to other immune cells to sites of bound
antigen, release of inflammatory mediators, endocytosis, and
phagocytosis. In contrast, it is likely that the protection conferred
by the IgY/IgYDFc involves only the virus-binding region of the
antibody and not any additional effector functions. This is because
the majority of the Fc region is naturally absent and what remains
is likely incompatible with the mammalian Fc receptors [37].
Although this Fc- property likely reduces the antiviral potency of
the product, it also likely reduces the reactogenicity of the product.
This is because the Fc region of heterologous antibodies plays a
Figure 6. 12,000 NAU/kg of anti-ANDV duck IgY/IgYDFc protects hamsters from lethal HPS disease. A) Survival curve of hamsters that
were challenged with 200 PFU i.m. of ANDV on day 0 and passively transferred with a-ANDV FFP (8 hamsters per group) or a-ANDV duck IgY/IgYDFc
(16 hamsters per group) on day 5 postinfection. * indicates statistical significance when compared to normal IgY/IgYDFc treatment. B) a-N ELISA
endpoint titers (log10) were conducted with sera from surviving hamsters challenged with ANDV in A). GMT for each group are shown.
doi:10.1371/journal.pone.0035996.g006
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will be required to determine if the duck IgY/IgYDFc is less
reactogenic than Ig or despeciated Ig produced in equine or ovine
derived polyclonal antibodies.
Nucleocapsid ELISAs conducted with serum from surviving
hamsters shows that hamsters passively transferred with the higher
doses of a-ANDV FFP on days 5 or 8 had low or undetectable
levels of a-nucleocapsid antibodies 1 month after challenge. This
was unexpected because 250 LD50 of ANDV had been in vivo for
several days before treatment and it seemed probable that enough
replication would have occurred elicit a robust a-N response. The
low a-N titers in the hamsters administered high doses of
neutralizing antibodies after i.n. exposure indicates that ANDV
does not replicate at high levels and disseminate immediately after
intranasal infection. This argument is supported by a recent
publication by Safronetz, et. al., stating that Andes virus RNA is
not detected in the blood until a few days before the animals
succumb following intranasal challenge. Also, the authors show a
suppression of the early innate immune response in most organs
[38]. Therefore, a high dose of neutralizing antibodies adminis-
tered to hamsters within 8 days after exposure to ANDV
apparently is sufficient to contain and suppress the infection. In
contrast, if the neutralizing antibody dosage is lower as in the case
of the a-ANDV rabbit sera (Fig. 2), then the treatment is capable
of protecting the hamsters against lethal disease, but not against a
level of ANDV amplification sufficient to elicit a robust a-N
antibody response.
A major implication of this work is that duck antibody can
function as an a-ANDV postexposure prophylactic. To be
practical, this would require scaling up production to meet
demand. We demonstrated that 5,000 NAU/kg of a-ANDV FFP
was able to protect 100% of hamsters from lethal HPS disease if
administered as late as 8 days after exposure. When scaled up for a
70 kg human, a dose would be equivalent to 34 ml of a-ANDV
FFP, with 13 doses per unit of blood. A more conservative
approach would be to administer 12,000 NAU/kg of a-ANDV
FFP, which not only protected against lethal disease, but also
limited the infection as measured by seroconversion. A 12,000
NAU/kg dose corresponds to 82 ml of a-ANDV FFP or five doses
per unit of blood. 12,000 NAU/kg of a-ANDV duck IgY/IgYDFc
was protective if administered within 5 days of exposure in the
ANDV/hamster model. Scaling this up for a 70 kg human, would
give a dose equal to 82 ml of purified a-ANDV duck IgY/IgYDFc,
at a concentration of 910 mg/dose. Duck egg yolks contain only
the IgY class of antibodies [24,37], with a potential yield of
100 mg of purified IgY from each egg yolk [25,39]. By vaccinating
ducks with the pWRG/AND-M DNA vaccine, hyperimmune egg
yolks containing IgYDFc can be manufactured on a larger scale,
without the need to bleed the duck. Based on the ,1,000 mg dose,
10 eggs would be required per dose. Using this rough estimate,
1,000 human doses would require 10,000 eggs. Ducks lay
approximately 5 eggs per week; therefore, it would take only
200 vaccinated ducks 10 weeks to produce 1,000 human doses.
Postexposure prophylaxis of suspected rabies virus infection
involves vaccination along with immunoglobulin treatment.
Passive transfer of anti-rabies immunoglobulin introduces neutral-
izing antibodies that are immediately able to combat the virus,
while the host is generating its own antibodies from the viral
antigens introduced through administration of the rabies vaccine.
A similar strategy could be employed for hantavirus infection. Co-
administering both the ANDV DNA vaccine and antibody
therapy postexposure would allow antibodies to neutralize virus
immediately while the host generates virus-specific antibodies from
vaccination. The use of a DNA vaccine, rather than an attenuated
virus vaccine, might be preferable because passively transferred
neutralizing antibodies would not inhibit the host response to
vaccination. In previous experiments, we observed that hamsters
treated with neutralizing antibodies from DNA-vaccinated mon-
key immune serum before ANDV exposure were either completely
protected against infection, or exhibited a significant delay in
death (i.e., mean day-to-death of 42 days versus 11 days for
hamsters treated with normal monkey sera) [14]. We hypothesized
that the delay in the disease course is due to incomplete
neutralization of virus after treatment with immune sera. As the
host clears the heterologous antibodies, the virus that escaped
neutralization by passive transfer is able to amplify, disseminate,
and eventually cause lethal HPS in the host. DNA vaccination
concurrent with antibody therapy could effectively prevent this
from occurring by eliciting an active immune response that would
eliminate virus that had escaped the initial passive transfer of
neutralizing antibodies.
Summary
Together, these experiments demonstrated that currently
available convalescent FFP can be used as a postexposure
prophylactic, and importantly, demonstrated that it is feasible to
use DNA vaccine technology coupled with the duck/egg system to
manufacture postexposure immunoprophylactics to prevent HPS.
The DNA vaccine-duck/egg system can be scaled as needed and
obviates the necessity of using limited blood products obtained
from a small number of HPS survivors. This is the first report
demonstrating the in vivo efficacy of any antiviral product produced
using the DNA vaccine-duck/egg system. Whether this system will
be viable as a means to develop products that are practical, safe,
and effective in humans will require further evaluation.
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